PDF(Pubmed)
Abstract：
Cardiac contractility modulation (CCM) is a Food and Drug Administration-approved device-based therapy for patients with heart failure. The system delivers biphasic electric stimulation to the ventricular myocardium during the absolute refractory period to augment left ventricular contraction. CCM therapy promotes acute and chronic changes at the cellular level, leading to favorable remodeling throughout the myocardium. CCM improves quality of life, New York Heart Association class, left ventricular ejection fraction, peak oxygen uptake, and the composite end point of cardiovascular death and heart failure hospitalizations. This review will focus on the biological basis, indications, and evidence for CCM, as well as the future applications of this technology.
摘要：
心脏收缩力调节（CCM）是食品和药物管理局批准的用于心力衰竭患者的基于设备的疗法。系统在绝对不应期期间向心室心肌递送双相电刺激以增强左心室收缩。CCM治疗促进细胞水平的急性和慢性变化，导致整个心肌的有利重塑。CCM提高了生活质量，纽约心脏协会班,左心室射血分数,峰值摄氧量,以及心血管死亡和心力衰竭住院的复合终点。这篇综述将集中在生物学基础上，适应症,和CCM的证据，以及该技术的未来应用。
